These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37665173)

  • 1. REG3A promotes proliferation and DDP resistance of ovarian cancer cells by activating the PI3K/Akt signaling pathway.
    Jiang L; Liu Y; Liu M; Zheng Y; Chen L; Shan F; Ji J; Cao Y; Kai H; Kang X
    Environ Toxicol; 2024 Jan; 39(1):85-96. PubMed ID: 37665173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
    Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
    Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
    Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
    Ma J; Liu L; Ling Y; Zheng J
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
    Yang H; Li H; Lu S; Shan S; Guo Y
    Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of REG3A on proliferation and invasion of glioma cells by regulating PI3K/Akt signaling pathway].
    Quan YC; Wang LY; Wang ZY; Gao W; Che FY
    Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):642-650. PubMed ID: 37580268
    [No Abstract]   [Full Text] [Related]  

  • 8. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
    Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
    Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M; Wang J; Guo Y; Yue H; Zhang L
    J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer.
    Wang Z; Li F; He S; Zhao L; Wang F
    Gene; 2022 Jan; 809():146003. PubMed ID: 34648915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.
    Ning Y; Zeng Z; Deng Y; Feng W; Huang L; Liu H; Lin J; Zhang C; Fan Y; Liu L
    Cancer Sci; 2021 May; 112(5):1785-1797. PubMed ID: 33788346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
    Xu L; Zhang B; Li W
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin.
    Xu Q; Liu Y; Wang S; Wang J; Liu L; Xu Y; Qin Y
    BMC Cancer; 2022 Jun; 22(1):628. PubMed ID: 35672728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer.
    Yang KD; Wang Y; Zhang F; Li QL; Luo BH; Feng DY; Zeng ZJ
    Mol Cell Biochem; 2022 Nov; 477(11):2493-2505. PubMed ID: 35588343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid differentiation factor 88 promotes cisplatin chemoresistance in ovarian cancer.
    Liu G; Du P; Zhang Z
    Cell Biochem Biophys; 2015 Mar; 71(2):963-9. PubMed ID: 25308861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation on the mechanism of the combination of eremias multiocellata and cisplatin in reducing chemoresistance of gastric cancer based on
    Cheng FE; Li Z; Bai X; Jing Y; Zhang J; Shi X; Li T; Li W
    Aging (Albany NY); 2024 Feb; 16(4):3386-3403. PubMed ID: 38345573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSAT1 Upregulation Contributes to Cell Growth and Cisplatin Resistance in Cervical Cancer Cells via Regulating PI3K/AKT Signaling Pathway.
    Duan W; Liu X
    Ann Clin Lab Sci; 2020 Jul; 50(4):512-518. PubMed ID: 32826249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
    Cai L; Zhang Q; Du L; Zheng F
    Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
    Yin S; Mai Z; Liu C; Xu L; Xia C
    Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.